Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal irinotecan plus FOLFOX and bevacizumab for extensive colorectal peritoneal carcinomatosis
NL-OMON50387Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of irinotecan in colorectal cancer (CRC) and peritoneal carcinomatosis (PC), sponsored by Erasmus MC. Primary endpoints: Maximum tolerated dose of intraperitoneal irinotecan and Recommended phase II dose of intraperitoneal irinotecan. Started Nov 2018; status: active, not recruiting.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NL-OMON50387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50387.